Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1
Cancer Letters · 2025-04 · 616 · 217567
DOI: 10.1016/j.canlet.2025.217567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-04. Verfasst von Lu Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University Sc…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cellular Senescence, Intracellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) treatment options remain limited despite advances in targeted therapies for molecularly-defined cancers. To address tumor heterogeneity, we reconstructed HCC clonal evolution through single-cell RNA sequencing trajectory analysis, identifying 902 signature genes across seven cellular states. Weighted gene co-expression network analysis of public HCC datasets revealed tumor-grade-associated modules and established a 14-gene prognostic model linked to clonal evolution. Central to this model is the LDHA-NDRG1 axis - two hypoxia-responsive regulators showing coordinated spatiotemporal expression patterns during cancer progression. Dual-expressing cell lineages correlated with poor prognosis and senescence resistance through LDHA-mediated lactylation of histone H2B at K58 on NDRG1, an epigenetic mechanism connecting metabolic reprogramming to senescence evasion. Therapeutically, dual inhibition of this axis extended survival in metastatic HCC murine models. Our findings reveal that lactate-driven epigenetic modification via the LDHA-NDRG1 axis creates a molecularly distinct subpopulation enabling senescence resistance, providing mechanistic insights into HCC heterogeneity. This work proposes a precision medicine strategy targeting lactylation-mediated epigenetic regulation, with implications for developing combination therapies and patient stratification based on clonal evolution patterns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China; Department of Nephrology, C…
- Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. Electronic address: dongjinyun@him.cas.cn.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310000, China. Electronic address: xuchunwei@him.cas.cn.
- Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China; Center for Innovative Drug…
Förderung
- China Postdoctoral Science Foundation
Zitieren
APA
Li, L., Dong, J., Xu, C., & Wang, S. (2025). Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1. Cancer Letters, 616, 217567. https://doi.org/10.1016/j.canlet.2025.217567
Vancouver
Li L, Dong J, Xu C, Wang S. Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1. Cancer Letters. 2025;616:217567. doi:10.1016/j.canlet.2025.217567
BibTeX
@article{Li2025,
author = {Li, Lu and Dong, Jinyun and Xu, Chunwei and Wang, Shiqun},
title = {Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1},
journal = {Cancer Letters},
year = {2025},
volume = {616},
pages = {217567},
doi = {10.1016/j.canlet.2025.217567}
}
EUVIMED